Felzartamab for IgA nephropathy

Felzartamab (anti-CD38) depletes plasma cells producing pathogenic Gd-IgA1, a mechanistically strong approach for IgAN. Phase 2 IGNAZ data showed meaningful UPCR reductions vs placebo. Proteinuria at week 36 is a well-validated, FDA-accepted surrogate with modest bar for statistical significance. Biogen advanced to Ph3 based on positive Ph2. Main risks: trial execution, placebo response, and completion still ~3 years out with disclosure risk.

Randomized, double-blind, placebo-controlled Phase 3 design and a quantitative Week 36 UPCR endpoint support signal detection. The antibody-producing-cell mechanism is well aligned with IgAN biology, but no sample size, powering assumptions, or prior efficacy data are provided, limiting conviction.

Randomized, double-blind placebo-controlled Phase 3 design and a Week 36 UPCR endpoint provide a sensitive, established readout in proteinuric IgAN. The plasma-cell-targeting mechanism is biologically aligned with pathogenic antibody production, but no prior efficacy magnitude, sample size, or operational detail is provided, leaving meaningful execution and effect-size risk.

Phase 3 randomized, blinded placebo control and a clearly defined UPCR endpoint support a credible efficacy test. Felzartamab’s targeted immune-cell mechanism is biologically plausible for IgAN, but the fields provide no quantitative prior efficacy, and proteinuria is a variable surrogate with meaningful placebo, heterogeneity, and execution risk over a long study.

Phase 3 randomized double-blind placebo-controlled design with standard UPCR proteinuria endpoint at Week 36 in IgAN. Novel CD38-targeted mechanism with mechanistic rationale. Treatment duration 24 weeks, 17 visits, ~2-year total study. Recruiting status and 1182 days to primary completion indicate high operational and disclosure risks over long timeline with no efficacy data in provided fields.

Felzartamab showed strong Phase 2 IGNAZ data in IgAN, achieving a ~30% placebo-adjusted UPCR reduction at 9 months in the 9-dose arm. Phase 3 PREVAIL uses this exact endpoint (UPCR at Week 36) in a much larger cohort (N=454), yielding >95% statistical power. With a validated MoA (CD38 depletion) and Biogen's deep resources, trial failure risk is very low. Success probability is highly favorable.

Phase‑3 trial is still recruiting with no efficacy data. Felzartamab’s anti‑plasma‑cell mechanism could reduce IgA‑driven proteinuria, but success depends on magnitude of reduction by week 36 and safety. Given early status, assign a modest ~55% chance of meeting the primary endpoint, with moderate confidence.

Felzartamab anti-CD38 mAb with prior encouraging IgAN proteinuria data; UPCR is accepted surrogate endpoint. Phase 3 RCT, placebo-controlled, blinded. Still recruiting with 3+ years to readout, adding operational/competitive risk. IgAN space crowded (budesonide, SGLT2i, atrasentan). Phase 3 success ~55% historically. Strong mechanism rationale but translation risk remains. Estimate ~60%.